Who are SM-13496 (lurasidone HCl)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SAMIDORPHAN L-MALATE, Lybalvi, Caplyta, Nuplazid, Rexulti, Vraylar.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sm-13496-lurasidone-hcl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

SM-13496 (lurasidone HCl) — Competitive Intelligence Brief

SM-13496 (lurasidone HCl) (SM-13496 (lurasidone HCl)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: atypical antipsychotic. Area: Psychiatry.

phase 3 atypical antipsychotic serotonin 2A receptor, dopamine D2 receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

SM-13496 (lurasidone HCl) (SM-13496 (lurasidone HCl)) — Sumitomo Pharma Co., Ltd.. SM-13496 (lurasidone HCl) is an atypical antipsychotic that acts as a serotonin 2A receptor antagonist and a dopamine receptor antagonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SM-13496 (lurasidone HCl) TARGET	SM-13496 (lurasidone HCl)	Sumitomo Pharma Co., Ltd.	phase 3	atypical antipsychotic	serotonin 2A receptor, dopamine D2 receptor
SAMIDORPHAN L-MALATE	SAMIDORPHAN L-MALATE		marketed	Atypical Antipsychotic [EPC]	dopamine and serotonin type 2 (5HT2) receptors, opioid receptors	2021-01-01
Lybalvi	SAMIDORPHAN	Alkermes Inc	marketed	Atypical Antipsychotic [EPC]	Mu-type opioid receptor	2021-01-01
Caplyta	LUMATEPERONE	Intra-Cellular	marketed	Atypical Antipsychotic [EPC]	5-hydroxytryptamine receptor 2A	2019-01-01
Nuplazid	PIMAVANSERIN	Acadia Pharms Inc	marketed	Atypical Antipsychotic	5-hydroxytryptamine receptor 2A	2016-01-01
Rexulti	BREXPIPRAZOLE	Otsuka	marketed	Atypical Antipsychotic [EPC]	D(2) dopamine receptor	2015-01-01
Vraylar	CARIPRAZINE	AbbVie	marketed	Atypical Antipsychotic [EPC]	D(3) dopamine receptor	2015-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2031-08-23 — Lybalvi · 11351166 · US
2031-08-23 — Lybalvi · 11241425 · US
2031-08-23 — Lybalvi · 9126977 · US
2031-08-23 — Lybalvi · 10300054 · US
2031-08-23 — Lybalvi · 10716785 · US
2031-08-23 — Lybalvi · 11185541 · US
2031-08-23 — Lybalvi · 9517235 · US
2031-08-30 — Lybalvi · 9119848 · US
2032-02-13 — Lybalvi · 8778960 · US

Sponsor landscape (atypical antipsychotic class)

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 2 drugs in this class
AstraZeneca · 2 drugs in this class
Eli Lilly and Company · 1 drug in this class
University of Alabama at Birmingham · 1 drug in this class
Qilu Pharmaceutical Co., Ltd. · 1 drug in this class
Sumitomo Pharma Co., Ltd. · 1 drug in this class
CR-CSSS Champlain-Charles-Le Moyne · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SM-13496 (lurasidone HCl) — Competitive Intelligence Brief. https://druglandscape.com/ci/sm-13496-lurasidone-hcl. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab